Tegileridine for moderate-to-severe acute pain following abdominal surgery - A randomized, double-blind, phase 3 clinical trial

Q: What medication and target does the trial evaluate?

The trial evaluates tegileridine, a MOR-biased μ-opioid receptor agonist designed to provide analgesia with potentially fewer opioid-related adverse effects.

Q: How were patients assigned in this phase 3 study?

A total of 526 patients with postoperative pain after abdominal surgery were randomized to placebo, tegileridine (0.75 mg or 1.0 mg), or morphine under a randomized, double-blind design.

Q: What did the primary outcome show compared with placebo and morphine?

For the primary outcome of effective analgesia measured by SPID24 at rest over the first 24 hours, tegileridine produced significantly better pain reduction than placebo (all p<0.001) and was comparable to morphine.

Sep 29, 2026

Uploaded by Theodore

Phase 3 randomized, double-blind clinical trial evaluating tegileridine, a MOR-biased agonist, for moderate-to-severe acute postoperative pain after abdominal surgery. The study randomized 526 patients to placebo, tegileridine 0.75 mg, tegileridine 1.0 mg, or morphine. For effective analgesia (SPID24 at rest), tegileridine showed significantly greater pain reduction versus placebo (all p<0.001) and was comparable with morphine. Total pain relief at 24 h also favored tegileridine over placebo while maintaining a comparable profile to morphine and an acceptable safety pattern.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages13

Reading Time33 min

AccessFree to download

Summary

Introduction

Trial Design and Outcomes

Primary outcome: SPID24

Secondary outcome: pain relief at 24 h

Overall Conclusion

Article Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, doubleblind, phase 3 clinical trial Authors Tingting Wang, Yafeng Wang, Haihui Xie, ..., Jiaqiang Zhang, Jianbo Yu, Xiangdong Chen Correspondence [zhangjiq@zzu.edu.cn](zhangjiq@zzu.edu.cn) (J.Z.), [yujianbo11@126.com](yujianbo11@126.com) (J.Y.), [xdchen@hust.edu.cn](xdchen@hust.edu.cn) (X.C.) In brief Wang et al. demonstrate the clinical efficacy of tegileridine, an MOR-biased agonist, which is comparable to morphine. They provide data on analgesic effects of tegileridine in vivo (in rats) and in participants with moderateto-severe acute pain after abdominal surgery with an acceptable safety profile. • This trial assessed tegileridine for moderate-to-severe acute postoperative pain • Tegileridine was superior to placebo in analgesia and was comparable to morphine Wang et al., 2025, Cell Reports Medicine 6, 102477 December 16, 2025 © 2025 The Authors. Published by Elsevier Inc. [https://doi.org/10.1016/j.xcrm.2025.102477](https://doi.org/10.1016/j.xcrm.2025.102477) ll ll OPEN ACCESS Article Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial Tingting Wang,1,2,3,22 Yafeng Wang,1,2,3,22 Haihui Xie,4,22 Zhilin Wu,1,2,3 Shuchun Yu,5 Yangwen Ou,6 Mingjun Xu,7 Wanwei Jiang,8 Liang Ge,9 Ju Gao,10 Qiang Wang,11 Hexin Gao,12 Yanjuan Huang,13 Ping Zhao,14 Yonghao Yu,15 He Huang,16 Jinghua Ren,17 Zhengyuan Xia,18,19 Jiaqiang Zhang,20,* Jianbo Yu,21,* and Xiangdong Chen1,2,3,23,* 1Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 2Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 3Key Laboratory of Anesthesiology and Resuscitation (Huazhong University of Science and Technology), Ministry of Education, Wuhan, China 4Department of Anesthesiology, Affiliated Dongguan People’s Hospital of Southern Medical University, Dongguan, Guangdong 523018, China 5Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, China 6Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha 410013, China 7Department of Anaesthesiology, Beijing Obstetrics and Gynaecology Hospital, Capital Medical University, Beijing, China 8Department of Anesthesiology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province 116001, China 9Department of Anesthesiology, The First Hospital, Jilin University, Changchun, China 10Department of Anesthesiology, Clinical Medical College of Yangzhou University (Northern Jiangsu People’s Hospital), Yangzhou 225001, China 11Department of Anesthesiology & Center for Brain Science, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China 12Department of Anesthesiology, Maternal and Child Health Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang, Uygur Autonomous Region, China 13Department of Anesthesiology, Nanning Second People’s Hospital, Nanning 530031, China 14Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China 15Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin 300052, China 16Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China 17Department of Anesthesiology, The Second People’s Hospital of Yibin, Yibin, China 18State Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China 19Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China 20Department of Anesthesiology and Perioperative Medicine, Pe

FAQs

What medication and target does the trial evaluate?

The trial evaluates tegileridine, a MOR-biased μ-opioid receptor agonist designed to provide analgesia with potentially fewer opioid-related adverse effects.

How were patients assigned in this phase 3 study?

A total of 526 patients with postoperative pain after abdominal surgery were randomized to placebo, tegileridine (0.75 mg or 1.0 mg), or morphine under a randomized, double-blind design.

What did the primary outcome show compared with placebo and morphine?

For the primary outcome of effective analgesia measured by SPID24 at rest over the first 24 hours, tegileridine produced significantly better pain reduction than placebo (all p<0.001) and was comparable to morphine.

Sep 29, 2026

Uploaded by Theodore